No significant strengths identified
| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| AUPHAurinia Pharmaceuticals Inc. | 1.96B | 14.87 | 378.37 | 33.97% | 29.28% | 21.28% | 2.25% | 0.21 |
| ARGXargenx SE | 50.33B | 813.24 | 63.63 | 78.6% | 23.34% | 15.14% | 0.01 | |
| INVAInnoviva, Inc. | 1.48B | 19.76 | 54.89 | 15.54% | 32.78% | 12.61% | 12.75% | 0.65 |
| GLPGGalapagos N.V. | 2.24B | 34.03 | 30.38 | 14.99% | -151.94% | -15.16% | 0.00 | |
| PTGXProtagonist Therapeutics, Inc. | 5.3B | 84.75 | 20.04 | 6.24% | 21.94% | 7.11% | 3.45% | 0.02 |
| ALMSAlumis Inc. Common Stock | 2.84B | 24.17 | -2.33 | -11.08% | -63.71% | 0.12 | ||
| PHATPhathom Pharmaceuticals, Inc. | 1.17B | 14.98 | -2.83 | 80.01% | -186.53% | |||
| ORKAOruka Therapeutics, Inc. | 1.57B | 32.50 | -6.51 | -22.44% | 0.00 |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Sales/Revenue | 0 | 0 |
| Revenue Growth % | - | - |
| Cost of Goods Sold | 0 | 0 |
| COGS % of Revenue | - | - |
| Gross Profit | 0 | 0 |
| Gross Margin % | - | - |
| Gross Profit Growth % | - | - |
| Operating Expenses | 2.31M | 1.8M |
| OpEx % of Revenue | - | - |
| Selling, General & Admin | 2.3M | 1.55M |
| SG&A % of Revenue | - | - |
| Research & Development | 7.5K | 245.96K |
| R&D % of Revenue | - | - |
| Other Operating Expenses | 0 | 0 |
| Operating Income | -2.31M | -1.8M |
| Operating Margin % | - | - |
| Operating Income Growth % | - | 0.22% |
| EBITDA | -2.26M | -1.75M |
| EBITDA Margin % | - | - |
| EBITDA Growth % | - | 0.23% |
| D&A (Non-Cash Add-back) | 43.92K | 47.48K |
| EBIT | -2.31M | -1.8M |
| Net Interest Income | 15.88K | 28.71K |
| Interest Income | 15.88K | 28.71K |
| Interest Expense | 0 | 0 |
| Other Income/Expense | 15.88K | 28.71K |
| Pretax Income | -2.29M | -1.77M |
| Pretax Margin % | - | - |
| Income Tax | 0 | 0 |
| Effective Tax Rate % | 1% | 1% |
| Net Income | -2.29M | -1.77M |
| Net Margin % | - | - |
| Net Income Growth % | - | 0.23% |
| Net Income (Continuing) | -2.29M | -1.77M |
| Discontinued Operations | 0 | 0 |
| Minority Interest | 0 | 0 |
| EPS (Diluted) | 0.00 | 0.00 |
| EPS Growth % | - | - |
| EPS (Basic) | 0.00 | 0.00 |
| Diluted Shares Outstanding | 0 | 0 |
| Basic Shares Outstanding | 0 | 0 |
| Dividend Payout Ratio | - | - |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Total Current Assets | 1.2M | 1.1M |
| Cash & Short-Term Investments | 1.18M | 872.6K |
| Cash Only | 1.18M | 872.6K |
| Short-Term Investments | 0 | 0 |
| Accounts Receivable | 0 | 0 |
| Days Sales Outstanding | - | - |
| Inventory | 0 | 0 |
| Days Inventory Outstanding | - | - |
| Other Current Assets | 20.82K | 225.32K |
| Total Non-Current Assets | 811.74K | 950.97K |
| Property, Plant & Equipment | 33.22K | 120.45K |
| Fixed Asset Turnover | - | - |
| Goodwill | 0 | 0 |
| Intangible Assets | 769.94K | 821.93K |
| Long-Term Investments | 0 | 0 |
| Other Non-Current Assets | 8.58K | 8.58K |
| Total Assets | 2.01M | 2.05M |
| Asset Turnover | - | - |
| Asset Growth % | - | 0.02% |
| Total Current Liabilities | 489.78K | 707.93K |
| Accounts Payable | 0 | 0 |
| Days Payables Outstanding | - | - |
| Short-Term Debt | 0 | 0 |
| Deferred Revenue (Current) | 0 | 0 |
| Other Current Liabilities | 464.62K | 667.27K |
| Current Ratio | 2.45x | 1.55x |
| Quick Ratio | 2.45x | 1.55x |
| Cash Conversion Cycle | - | - |
| Total Non-Current Liabilities | 1.44M | 1.52M |
| Long-Term Debt | 0 | 0 |
| Capital Lease Obligations | 0 | 80.38K |
| Deferred Tax Liabilities | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 |
| Total Liabilities | 1.93M | 2.23M |
| Total Debt | 25.16K | 121.04K |
| Net Debt | -1.16M | -751.56K |
| Debt / Equity | 0.29x | - |
| Debt / EBITDA | - | - |
| Net Debt / EBITDA | - | - |
| Interest Coverage | - | - |
| Total Equity | 85.77K | -177.43K |
| Equity Growth % | - | -3.07% |
| Book Value per Share | - | - |
| Total Shareholders' Equity | 85.77K | -177.43K |
| Common Stock | 1.32K | 1.34K |
| Retained Earnings | -17.43M | -19.2M |
| Treasury Stock | 0 | 0 |
| Accumulated OCI | 0 | 0 |
| Minority Interest | 0 | 0 |
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Cash from Operations | -1.38M | -1.36M |
| Operating CF Margin % | - | - |
| Operating CF Growth % | - | 0.01% |
| Net Income | -2.29M | -1.77M |
| Depreciation & Amortization | 43.92K | 47.48K |
| Stock-Based Compensation | 640.26K | 352.83K |
| Deferred Taxes | 0 | 0 |
| Other Non-Cash Items | 662 | 8.65K |
| Working Capital Changes | 229.74K | -1.86K |
| Change in Receivables | 0 | 0 |
| Change in Inventory | 0 | 0 |
| Change in Payables | 0 | 0 |
| Cash from Investing | -44.31K | -99.47K |
| Capital Expenditures | -44.31K | -99.47K |
| CapEx % of Revenue | - | - |
| Acquisitions | - | - |
| Investments | - | - |
| Other Investing | 0 | 0 |
| Cash from Financing | 500K | 1.15M |
| Debt Issued (Net) | - | - |
| Equity Issued (Net) | - | - |
| Dividends Paid | 0 | 0 |
| Share Repurchases | - | - |
| Other Financing | 0 | 0 |
| Net Change in Cash | - | - |
| Free Cash Flow | -1.42M | -1.46M |
| FCF Margin % | - | - |
| FCF Growth % | - | -0.03% |
| FCF per Share | - | - |
| FCF Conversion (FCF/Net Income) | 0.60x | 0.77x |
| Interest Paid | 0 | 0 |
| Taxes Paid | 0 | 0 |
| Metric | 2023 | 2024 |
|---|---|---|
| Return on Equity (ROE) | -2672.64% | - |
| Debt / Equity | 0.29x | - |
| FCF Conversion | 0.60x | 0.77x |
Turn Therapeutics Inc. (TTRX) grew revenue by 0.0% over the past year. Growth has been modest.
Turn Therapeutics Inc. (TTRX) reported a net loss of $1.8M for fiscal year 2024.
Turn Therapeutics Inc. (TTRX) had negative free cash flow of $1.5M in fiscal year 2024, likely due to heavy capital investments.